(MedPage Today) — WASHINGTON — Elafibranor (Iqirvo) was well tolerated and led to sustained improvements in liver enzyme levels and itch severity through 28 weeks in patients with primary sclerosing cholangitis (PSC), according to interim results…
Source link : https://www.medpagetoday.com/meetingcoverage/aasld/118401
Author :
Publish date : 2025-11-09 21:16:00
Copyright for syndicated content belongs to the linked Source.
